References

1. Nagel RL, Fabry ME, Steinberg MH. The paradox of hemoglobin SC disease. Blood Rev. 2003; 17(3): 167-78. PubMed | Google Scholar


2. Markham MJ, Lottenberg R, Zumberg M. Role of phlebotomy in the management of hemoglobin SC disease: case report and review of the literature. Am J Hematol. 2003; 73(2): 121-5. PubMed | Google Scholar


3. Bouchaïr N, Manigne P, Kanfer A, Raphalen P, de Montalembert M, Hagege I, Verschuur A, Maier-Redelsperger M, Girot R. Prevention of sickle cell crises with multiple phlebotomies. Arch Pediatr. 2000; 7(3): 249-55. PubMed | Google Scholar


4. OMS. Conseil exécutif EB118/5.Thalassémie et autres hémoglobinopathies. 11 mai 2006. Google Scholar


5. Condon PI, Serjeant GR. Behaviour of untreated proliferative sickle retinopathy. Br J Ophthalmol. 1980; 64(6): 404-11. PubMed | Google Scholar


6. Downes SM, Hambleton IR, Chuang EL, Lois N, Serjeant GR, Bird AC. Incidence and natural history of proliferative sickle cell retinopathy: observations from a cohort study.Ophthalmology. 2005; 112(11): 1869-75. PubMed | Google Scholar


7. Koduri PR, Agbemadzo B, Nathan S. Hemoglobin S-C disease revisited: clinical study of 106 adults. Am J Hematol. 2001; 68(4): 298-300. PubMed | Google Scholar


8. Cao J, Mathews MK, McLeod DS, Merges C, Hjelmeland LM, Lutty GA. Angiogenic factors in human proliferative sickle cell retinopathy. Br J Ophthalmol. 1999; 83(7): 838-46. PubMed | Google Scholar